Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07675044 · ClinicalTrials.gov registry record
Quantifying the Burden of Type 2 (T2) Inflammation in Asthma
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Not yet
- Registry status
- 200
- Enrollment target
NCT07675044 is a clinical trial that has not yet begun recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 200 participants.
The verdict
NCT07675044 has not yet begun recruiting, sponsored by Icahn School of Medicine at Mount Sinai.
- NOT YET RECRUITING
- Registry status
- 200 participants
- Enrollment target
Study Summary
This study is designed to support the assessment of Type 2 (T2) biomarkers in asthma in primary care and community specialty practices. To assess T2 biomarkers, individuals will be required to complete a breath test for fractional exhaled nitric oxide (FeNO) and consent to a review of their medical records. Asthma often goes undetected in primary care and community settings, and through this study the researchers hope to optimize referral pathways to care.
Interventions
- DIAGNOSTIC_TEST FeNO Breath Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07675044
The ClinicalTrials.gov registry entry for NCT07675044 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FeNO Breath Test is the first listed.
NCT07675044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07675044 about?
NCT07675044 is a clinical study titled "Quantifying the Burden of Type 2 (T2) Inflammation in Asthma". This study is designed to support the assessment of Type 2 (T2) biomarkers in asthma in primary care and community specialty practices. To assess T2 biomarkers, individuals will be required to complete a breath test for fractional exhaled nitric oxide (FeNO) and consent to a review of their medical ...
What is the current status of trial NCT07675044?
This trial is currently not yet recruiting. The enrollment target is 200 participants. The study started on 2026-07. Estimated completion is 2027-05.
What interventions are being tested in trial NCT07675044?
The interventions under investigation include: FeNO Breath Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07675044?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.